Previous studies suggest that central arginine vasopressin (AVP) signaling can inhibit the hypothalamic–pituitary–adrenal (HPA) axis. To test a role for the AVP V1A receptor in stress HPA axis ...

Since hyperactivity of vasopressin has been implicated as an ... signals were diluted by patients who had no problem with the HPA axis. Thus, there is a tool to overcome the disturbance, if ...

The double-blind trial is claimed to be the 'largest' precision psychiatry trial to assess a vasopressin V1b receptor ... needs of MDD patients with HPA-axis dysfunction. “The outcome of the ...

a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who have underlying HPA-axis (Hypothalamus‐pituitary‐adrenal axis) dysfunction. The neuropeptide ...

“So, why were we required to test for possible HPA axis suppression in the first place?” Data derived from Bhatia N, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7997. According to ...

The trial is investigating the efficacy and safety of BH-200, a potent vasopressin V1b receptor ... which aims to address MDD in patients with HPA-axis dysfunction—a subgroup comprising ...

About the Nelivabon Program The Nelivabon program is focused on developing BH-200, a vasopressin V1b receptor antagonist, to treat Major Depressive Disorder (MDD) related to dysfunction in the human ...